Categories Earnings, Health Care

Abbott Laboratories net earnings soar in first quarter

Abbott Laboratories (ABT) announced its first-quarter 2019 earnings results on Wednesday, April 17, before the opening bell.

In the three-month period, worldwide sales grew 2% to $7.5 billion, with earnings from continuing operations jumping 65% to 38 cents per diluted share. Adjusted diluted EPS from continuing operations improved by 6.3% to $0.63.

Total net earnings jumped 61% year-over-year to $672 million.

Abbott Laboratories Q1 earnings soar

Back in January, Abbott also received the FDA approval for a “new, expanded indication” for its MitraClip device to treat clinically significant secondary mitral regurgitation — a leaky heart valve resulting from advanced heart failure.

Then in March, Abbott obtained the CE Mark for its Alinity (molecular) diagnostics system and testing assays to aid in infectious disease testing.

“We’re right on track with our expectations to start the year,” said Abbott CEO Miles D. White, “…all of our key long-term growth drivers are performing well and we’re targeting another year of strong sales and earnings growth.”

Abbott now projects full-year 2019 GAAP earnings to be between $1.95 to $2.05 per diluted share, and adjusted diluted earnings from continuing operations to be $3.15-3.25 per share for the same period.

For the second quarter of 2019, Abbott sees GAAP diluted EPS of $0.47-0.49, and projects adjusted diluted earnings from continuing operations of $0.79-0.81 per share.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Broadcom (AVGO) seems a good buy ahead of VMware deal. Here’s why

The performance of Broadcom, Inc. (NASDAQ: AVGO) has been impressive in the last few years -- a period of high uncertainty -- as the successful business model helped it remain

Delta Air Lines (DAL): A look at the airline’s expectations for the near term

Shares of Delta Air Lines Inc. (NYSE: DAL) were down 2% on Monday. The stock has dropped 12% year-to-date. The company delivered double-digit revenue growth for its most recent quarter

Why it’s a good idea to keep an eye on Autodesk (ADSK) stock

Autodesk, Inc. (NASDAQ: ADSK) is a market leader in computer-assisted design software, catering mainly to the architecture, engineering, construction, and manufacturing sectors with its mission-critical solutions. The company, which is

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top